Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...

Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

WEDNESDAY, March 19, 2025 (HealthDay News) -- Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...